| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| General and administrative | 13,816 | |||
| Research and development | 37,592 | |||
| Total operating expenses | 51,408 | |||
| Operating loss | -51,408 | |||
| Grant income | 37 | |||
| Research and development incentive income | 648 | |||
| Interest income, net | 4,678 | |||
| Foreign exchange gain (loss) | -332 | |||
| Total other income, net | 5,031 | |||
| Net loss and comprehensive loss | -46,377 | |||
| Net loss per share, basic | -0.54 | |||
| Net loss per share, diluted | -0.54 | |||
| Weighted average number of shares outstanding, basic | 85,289,447 | |||
| Weighted average number of shares outstanding, diluted | 85,289,447 | |||
ANAVEX LIFE SCIENCES CORP. (AVXL)
ANAVEX LIFE SCIENCES CORP. (AVXL)